Bristol-Myers puts up Opdivo-plus-Yervoy data, adding to combo-therapy mystery
admin 16th August 2017 Uncategorised 0If you’re looking for certainty in immuno-oncology, Bristol-Myers’ latest data won’t help. The drugmaker reported mixed results from Opdivo-plus-Yervoy in a kidney cancer test, raising questions about its bid for a first-line approval in that field.
More: Bristol-Myers puts up Opdivo-plus-Yervoy data, adding to combo-therapy mystery
Source: fierce